Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist
S. Birring (London, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), J. Smith (Manchester, United Kingdom), A. Morice (Cottingham, United Kingdom), M. Sher (Largo, United States of America), W. Wu (Kenilworth, United States of America), Z. Xu (Kenilworth, United States of America), A. Nguyen (Kenilworth, United States of America), J. Schelfhout (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America)
Source: International Congress 2019 – Highlights in lung function and chronic cough
Session: Highlights in lung function and chronic cough
Session type: Poster Discussion
Number: 613
Disease area: Airway diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Birring (London, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), J. Smith (Manchester, United Kingdom), A. Morice (Cottingham, United Kingdom), M. Sher (Largo, United States of America), W. Wu (Kenilworth, United States of America), Z. Xu (Kenilworth, United States of America), A. Nguyen (Kenilworth, United States of America), J. Schelfhout (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America). Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist. 613
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: